Search Results - "Mojcik, Christopher F"

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria by Rother, Russell P, Rollins, Scott A, Mojcik, Christopher F, Brodsky, Robert A, Bell, Leonard

“…The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In…”
Get full text

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria by Hillmen, Peter, Young, Neal S, Schubert, Jörg, Brodsky, Robert A, Socié, Gerard, Muus, Petra, Röth, Alexander, Szer, Jeffrey, Elebute, Modupe O, Nakamura, Ryotaro, Browne, Paul, Risitano, Antonio M, Hill, Anita, Schrezenmeier, Hubert, Fu, Chieh-Lin, Maciejewski, Jaroslaw, Rollins, Scott A, Mojcik, Christopher F, Rother, Russell P, Luzzatto, Lucio

“…In this randomized trial, eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, was compared with placebo as a…”
Get full text

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria by Hill, Anita, Hillmen, Peter, Richards, Stephen J., Elebute, Dupe, Marsh, Judith C., Chan, Jason, Mojcik, Christopher F., Rother, Russell P.

“…Paroxysmal nocturnal hemoglobinuria (PNH) is a hematologic disorder characterized by clonal expansion of red blood cells (RBCs) lacking the ability to inhibit…”
Get full text

Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction : results from the CARDINAL study by VOGELZANG, Mathijs, ZIJISTRA, Felix, TODARO, Thomas G, MOJCIK, Christopher F, ARMSTRONG, Paul W, GRANGER, Christopher B, GOYAL, Abhinav, MAHAFFEY, Kenneth W, GARG, Jyotsna, NICOLAU, Jose C, HOCHMAN, Judith S, WEAVER, W. Douglas, THEROUX, Pierre, OLIVEIRA, Gustavo B. F

“…In acute myocardial infarction (AMI), baseline hyperglycaemia predicts adverse outcomes, but the relation between subsequent change in glucose levels and…”
Get full text

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial by Winthrop, Kevin L., Wouters, Ann G., Choy, Ernest H., Soma, Koshika, Hodge, Jennifer A., Nduaka, Chudy I., Biswas, Pinaki, Needle, Elie, Passador, Sherry, Mojcik, Christopher F., Rigby, William F.

“…Objective Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster, and vaccination is recommended for patients ages 50 years and older,…”
Get full text

Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis by BUCKLAND-WRIGHT, J. Chris, WARD, Rupert J, PETERFY, Charles, MOJCIK, Christopher F, LEFF, Richard L

“…OBJECTIVE: To determine the baseline and longitudinal consistency in reproducibility of the semiflexed metatarsophalangeal (MTP) position in repeat…”
Get full text

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers by Weinhold, Kent J., Bukowski, Jack F., Brennan, Todd V., Noveck, Robert J., Staats, Janet S., Lin, Liwen, Stempora, Linda, Hammond, Constance, Wouters, Ann, Mojcik, Christopher F., Cheng, John, Collinge, Mark, Jesson, Michael I., Hazra, Anasuya, Biswas, Pinaki, Lan, Shuping, Clark, James D., Hodge, Jennifer A.

“…This study evaluated the short-term effects of tofacitinib treatment on peripheral blood leukocyte phenotype and function, and the reversibility of any such…”
Get full text

Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria by Hillmen, Peter, Hall, Claire, Marsh, Judith C.W, Elebute, Modupe, Bombara, Michael P, Petro, Beth E, Cullen, Matthew J, Richards, Stephen J, Rollins, Scott A, Mojcik, Christopher F, Rother, Russell P

“…The cause of the hemolytic anemia of paroxysmal nocturnal hemoglobinuria (PNH) is excessive susceptibility of erythrocytes to the lytic effects of the…”
Get full text

Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass: A Randomized Trial by Verrier, Edward D, Shernan, Stanton K, Taylor, Kenneth M, Van de Werf, Frans, Newman, Mark F, Chen, John C, Carrier, Michel, Haverich, Axel, Malloy, Kevin J, Adams, Peter X, Todaro, Thomas G, Mojcik, Christopher F, Rollins, Scott A, Levy, Jerrold H, for the PRIMO-CABG Investigators

“…CONTEXT Inflammation and ischemia-reperfusion injury during coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass are associated with…”
Get full text

Aprotinin and the systemic inflammatory response after cardiopulmonary bypass by Mojcik, Christopher F, Levy, Jerrold H

“…Cardiopulmonary bypass is associated with a systemic inflammatory response, a spectrum of pathophysiologic changes ranging from mild organ dysfunction to…”
Get full text

Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial by MAHAFFEY, Kenneth W, GRANGER, Christopher B, ARMSTRONG, Paul W, NICOLAU, Jose C, RUZYLLO, Witold, WEAVER, W. Douglas, THEROUX, Pierre, HOCHMAN, Judith S, FILLOON, Thomas G, MOJCIK, Christopher F, TODARO, Thomas G

“…Complement activation mediates myocardial damage that occurs during ischemia and reperfusion through multiple pathways. We performed 2 separate, parallel,…”
Get full text

Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass by Shernan, Stanton K, Fitch, Jane C.K, Nussmeier, Nancy A, Chen, John C, Rollins, Scott A, Mojcik, Christopher F, Malloy, Kevin J, Todaro, Thomas G, Filloon, Thomas, Boyce, Steven W, Gangahar, Deepak M, Goldberg, Michael, Saidman, Lawrence J, Mangano, Dennis T

“…During cardiac surgery requiring cardiopulmonary bypass, pro-inflammatory complement pathways are activated by exposure of blood to bio-incompatible surfaces…”
Get full text

End-stage renal disease and systemic lupus erythematosus by Mojcik, C F, Klippel, J H

“…To provide an overview of the course of systemic lupus erythematosus (SLE) following the onset of end-stage lupus nephropathy, regarding clinical and…”
Get more information

The Effectiveness of Zoster Vaccine in Patients Subsequently Treated With Tofacitinib: 748 by Winthrop, Kevin L., Wouters, Ann, Choy, Ernest H., Nduaka, Chudy I., Biswas, Pinaki, Wang, Lisy, Hodge, Jennifer A., Lazariciu, Irina, Soma, Koshika, Mojcik, Christopher F., Rigby, William F.C.

Get full text

Successful Treatment of Hemolysis and Severe Anemia without Transfusion in a Jehovah's Witness PNH Patient with the Terminal Complement Inhibitor Eculizumab by Glasser, Robert M., Mojcik, Christopher F.

“…In hemolytic paroxysmal nocturnal hemoglobinuria (PNH) patients, hemoglobin levels are typically maintained by transfusions, without which severe anemia can…”
Get full text

Erratum: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria by Rother, Russell P, Rollins, Scott A, Mojcik, Christopher F, Brodsky, Robert A, Bell, Leonard

Get full text

Role of Endogenous Retroviruses in Autoimmune Diseases by GOURLEY, MARK F., KISCH, WENDY J., MOJCIK, CHRISTOPHER F., KING, LESLIE B., KRIEG, ARTHUR M., STEINBERG, ALFRED D.

“…GOURLEY, M.F., KISCH, W.J., MOJCIK, C.F., KING, L.B., KRIEG, A.M. and STEINBERG, A.D. Role of Endogenous Retroviruses in Autoimmune Diseases. Tohoku J. Exp…”
Get full text

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study by Young, Neal S., Antonioli, Elisabetta, Rotoli, Bruno, Schrezenmeier, Hubert, Schubert, Jörg, Urbano-Ispizua, Alvaro, Coyle, Luke, de Castro, Carlos, Fu, Chieh-Lin, Maciejewski, Jaroslaw P., Mojcik, Christopher F., Rother, Russell P., Hillmen, Peter

“…In paroxysmal nocturnal hemoglobinuria (PNH), lack of the GPI-anchored terminal complement inhibitor CD59 from blood cells renders erythrocytes susceptible to…”
Get full text

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results by Schubert, Jörg, Hillmen, Peter, Dührsen, Ulrich, Young, Neal S., Elebute, Modupe, Szer, Jeffrey, Gianfaldoni, Giacomo, Socié, Gérard, Browne, Paul, Mojcik, Christopher F., Rother, Russell P., Muus, Petra

“…Paroxysmal nocturnal hemoglobinuria (PNH) is a potentially life-threatening acquired hemolytic anemia in which red blood cells (RBCs) lacking complement…”
Get full text

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Commentary by HILL, Anita, HILLMEN, Peter, RICHARDS, Stephen J, ELEBUTE, Dupe, MARSH, Judith C, CHAN, Jason, MOJCIK, Christopher F, ROTHER, Russell P, BESSLER, Monica

Get full text